Coloplast ASCLPBF 72 EBITDA Margin % is 32.37% as of Mar. 2026, which is 2% above its 10-year median of 31.86. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.91 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Coloplast AS ranks better than 92.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Coloplast AS's EBITDA for the
three
months ended in Mar. 2026 was $355 Mil. Coloplast AS's Revenue for the
three
months ended in Mar. 2026 was $1,096 Mil. Therefore, Coloplast AS's EBITDA margin for the quarter that ended in Mar. 2026 was 32.37%.
Coloplast AS (OTCPK:CLPBF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Coloplast AS EBITDA Margin % Related Terms
Coloplast AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Coloplast AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Coloplast AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a EBITDA Margin % of 32.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Coloplast AS and its competitors. This is near median its historical median of 31.86. Over the past decade, Coloplast AS's EBITDA Margin % has ranged from 30.00 to 36.29. According to the industry distribution chart, Coloplast AS ranks #64 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 7.8%.
Is Coloplast AS's EBITDA Margin % too high?
Coloplast AS's current EBITDA Margin % of 32.37% is near median its 10-year median of 31.86. Over the past 10 years, this metric has ranged from a low of 30.00 to a high of 36.29. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Coloplast AS's value of 32.37% is 333% above this industry median. Based on the distribution chart, Coloplast AS ranks #64 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #64 out of 816 companies for EBITDA Margin %. This places Coloplast AS in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Coloplast AS's value of 32.37% is 333% above this benchmark. Historically, Coloplast AS's own EBITDA Margin % has ranged from 30.00 to 36.29 over the past decade. While the company's 10-year median is 31.86 vs. the industry median of 7.48, Coloplast AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current EBITDA Margin % of 32.37% is 333% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current EBITDA Margin % is 32.37%, which is near median its own 10-year median of 31.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.91, compared to a current price of $57.41 — trading 54.8% below its estimated fair value. The current EBITDA Margin % is 32.37%, which is near median its 10-year median of 31.86 and 333% above the Medical Devices & Instruments industry median of 7.48. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current EBITDA Margin % is 32.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $57.41 is trading 54.8% below its estimated GF Value™ of $126.91.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
EBITDA Margin %: 32.37% (near median its 10-year median of 31.86)
GF Value™: $126.91 vs. price of $57.41 (54.8% below fair value)
Industry Position: 333% above the Medical Devices & Instruments median (#64 of 816)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
